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     One of the most important aspects in recombinant biologic production, based on GMP rules, is the 
accuracy of final product quality control, especially assessment of host cell macromolecules 
contamination rate in final product. The purification requirement can be eliminated when the yeast 
cell containing the recombinant protein is used as a host cell. It is possibile that the final product 
contaminated  to the host cell protein during purification stages of HBsAg (HBV vaccine). The 
protein purification costs depend on the purification  procedures required. Nowadays several 
companies produce commercial kits for identification and assessment of host cell protein 
contamination based on ELISA and Western blotting methods. But high prices, difference in 
sensitivity and lack of easy access to these kits sometimes create problems. So, in this study, two 
methods of Ammonium sulphate and caprilic acid precipitation technique were used separately for 
IgG purification. The results showed that IgG purification increased by 97% in caprylic acid method, 
compared with only a 77% increase in ammonium sulphate method. There were also significant 
differences in specificity and sensitivity between our standardized ELISA technique and using 
commercial kit (Cygnus CHO HCP).   
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INTRODUCTION 
Hepatitis B virus is one of several hepatitis 
viruses that cause a systemic infection, with 
a major pathology in the liver. These 
include hepatitis A virus, hepatitis B virus, 
and hepatitis C and E viruses, previously 
referred to as non-A, non-B hepatitis 
viruses. Hepatitis B virus is an important 
cause of viral hepatitis. Effective and safe 
hepatitis B virus vaccine was commercially 
available since 1982[1]. First vaccines were 
prepared by harvesting HBs Ag from the 
plasma of patients with chronic HBV 
infection. Then with the development of 
recombinant DNA technology, HBsAg was 
expressed in other organisms. Today, 
recombinant DNA vaccines are used in 
most countries [2, 3]. Hepatitis B virus 
vaccine contains 3 to 40 micrograms per 
liter of HBsAg protein and ammonium 
phosphate or aluminum hydroxide adjuvant 
[1].  The most widespread recombinant 
hepatitis B vaccine is a hepatitis B surface 
antigen (HBsAg) with 226 amino acids 
expressed in yeast Saccharomyces 
cerevisiae and Pichia pastoris [4,5] are used 
for preparation of recombinant hepatitis B 
vaccine [13], and due to advantages of Pichia 
pastoris over Saccharomyces cerevisiae, this 
yeast is used mostٰ [13,14]ٰ.   HBsAg produced in 
yeast, is purified by physical separation 
techniques, then yeast components are removed. 
There is possibility of contamination of final 
product to the host cell protein (yeast) in 
HBsAg purification stages [1, 8]. All yeast, 
plant and animal-derived recombinant 
proteins that are administered to human 
patients must be compared to their 
counterparts and rigorously tested for safety 
[5, 6]. Quality control of using materials, 
intermediate products and finally the finished 
product at different stages of vaccine production 
process, are the most important steps in the 




GMP principles. One of quality control tests in 
the production of recombinant hepatitis B 
vaccine is determining the final product 
contamination of host cell proteins (HCP) [7, 8]. 
According to WHO protocol and valid 
pharmacopoeia, this amount should not exceed 
0.1 Percent [9]. Since for production of 
recombinant products, especially hepatitis B 
vaccines, the recombinant DNA of host cells are 
used, even after the purification process, some 
impurities remains in these products. Although 
the infection rate may be low, but for protection 
of consumer health and prevention of immune 
response, contamination level should be 
decreased to the minimum amount (less than 
0.1%). Commercial reagents and generic 
analytical methods are available to quantity 
most of these contaminants that each of them 
possess advantages and disadvantages (Table 1) 
[10, 11]. Two current Immunological methods 
that use to assess the HCP contamination are 
Western blot and immunoassay [19]. Western 
blot is used to confirm the presence of infection 
(qualitative), while immunoassay is effective 
for determination of the contamination rate 
(quantitative) [7, 12]. 
 
Table1: comparison of purification methods. 
Method Advantages Limitation 
SDS-PAGE/ 
Silver stain 
Good sensitivity 100pg/bandresolves, multiple 
Components 
Subjective, interpretation 
qualitative, complex, and 
technique-dependent 
HPLC High resolution 
Low sensitivity, nonspecific, 
Quantitative 
Western blot 
Immunological identity resolves 
multiple components sensitivity 
0.1–1 ng/band 
Qualitative, very complex 
antibody may fail to 
detect some contaminants 
Immunoassay 
High sensitivity ng/mL 
quantitative, 
objective endpoint 
No resolution of individual 
components, antibody may 
fail to detect some 
Contaminants 
 
Nowadays there are commercial kits that 
recognize host cell proteins by using polyclonal 
antibodies [8.11]. In general, in biological 
production, including pharmaceutical, food or 
products that are used in diagnostic kits, 
purification and filtration are the most expensive 
stages, so it seems that in commercial kits for 
detection of recombinant hepatitis B vaccine 
pollutant proteins, rabbit blood hyper immune 
total serum is used in order to decrease production 
costs [4, 13]. Therefore use of purified and mono-
specific antibodies can significantly increase 
results reliability, because in comparison with 
commercial kits sensitivity and specificity are 
better [15, 17]. The present research has been 
done at Pasteur Institute of Iran to increase the 
sensitivity and specificity of HCP contamination 
detection test. 
MATHERIALS & METHODS  
Yeast strains   
Recombinant Pichia pastoris (W-3160) and non-
transgenic   Saccharomyces cerevisiae (CSBPI-d-
41) (as negative control) were obtained from 
microbial strains maintenance center of Pasteur 




Preparation of specific Pichia pastoris 
antiserum   
 
 In order to prepare Pichia pastoris lysate for 
injection, yeast was placed in YPG broth medium 
(1% yeast extract, 2% peptone and 2% glucose) at 
30ºc on the shaker for 72 hours[15,17]. Then 0.5 
mm of glass seeds was added and spin at 2 to 5°c. 
Yeast lysate was administered by subcutaneously 
injection. So, 0.5ml of cell lysate was emulsified 
with complete Freunds Adjuvant and was injected 
into white albino rabbits. This procedure was 
repeated twice, after 14 and 28 days after the first 
immunization. After one week, the animals were 
bled and blood serum was maintained at - 20°c [5, 
19, 20]. 
Separation of Immunoglobulin 
Two methods were used: 
A) Antibody purification using ammonium sulfate 
precipitation: 
10 ml of saturated of ammonium sulfate  (100 g 
ammonium sulfate powder in 100 ml distilled 
water) was added to 20 ml of prepared serum. 
This solution was centrifuged for 10 minute 
at1000 rpm. The supernatant discarded and 
precipitation was solved  with  5 ml phosphate 
buffer with pH = 7 (16 g sodium chloride, 4 g 




potassium chloride, 23 g di-sodium hydrogen 
phosphate and 4 g potassium dihydrogen 
phosphate) [5, 11, 22, 23].  
B) Antibody purification using Caprylic acid 
precipitation:  
In terms of yield of antibodies, precipitation 
with caprylic acid is comparable to sequential 
precipitation with ammonium sulfate method. In 
this method, 10 ml 0f prepared serum was 
added to 30 ml of 60mM sodium acetate and pH 
adjusted to 4.5 to 4.8 with HCl. 700 micro liter 
caprylic acid was added gently and solution was 
mixed by magnetic mixer at 25°c for 1 hour. 
Then supernatant containing antibody was 
isolated by centrifuge at 5000 rpm for 15 
minutes [23,24]. 
  
Ion Exchange Chromatography  
Total prepared protein was used for DEAE-
cellulose ion exchange chromatography. 
Chromatography was equilibrated with 
phosphat buffered saline pH=6.3. Then sample 
was used as feed and bound antibody was either 
eluted using phosphate buffered salin pH=6.3. 
Other attached proteins were separated by 
sodium chloride 1m [4, 6, 10, 22]. 
 
SDS-PAGE electrophoresis  
 Purified IgG was boiled in buffer sample 
without 2ME for 5 minutes. Also to confirm and 
further review a sample, purified IgG was 
boiled in buffer sample with 2ME. These 
samples separately were resolved by 10% 
sodium dodecyl sulfate polyacrylamide gel 
electrophoresis for 45 minutes at 14 mA, 
followed by electrophoretic transfer to 
nitrocellulose membrane [6, 22].  
Immunoblotting test  
For Western blotting, after protein transferring 
to nitrocellulose membranes, membranes were 
blocked and incubated with BSA 5% for 30 
minutes. After washing with phosphate buffered 
saline pH=7.2, membrane was incubated with 
appropriate primary antibodies (purified IGg) at 
room temperature for 1 hour, followed by 
incubation with anti-rabbit horseradish 
peroxidase (HRP)-conjugated antibodies. The 
probed proteins were detected using the 
chemiluminescent reagent. The bidimensional 
absorbance of proteins on the films were 
quantified and analyzed with Molecular Analyst 
software (Bio-Rad). In this bloting, control 
antibody was Pichia pastoris standard 
antibody11 [5, 12, 27]. 
ELISA   
ELISA was performed with the samples taken 
before, during and after purification in order to 
determine the concentration of the protein at 
stages of purification.  Polyclonal affinity 
purified anti pichia pastoris antibody was used 
for coating of ELISA plates. Conjugated IgG 
antibody was used as the primary antibody. 
Bound yeast antigen was detected by addition of 
peroxidase-conjugated anti-yeast antibody. 
ELISA readings (OD 450 nm) were performed 
after 1-10 min for detection of peroxidase 
[4,6,13,23,27]. 
Statistical analysis 
Quantitative comparisons of immunoblotting 
variables between purified antibody and kit 
were examined with the PRISM3 test and t test 
(p<0.0001). Continuous variables were 
dichotomized to facilitate our analysis [13, 27, 
23].  
RESULT 
IGg antibody purity was tested at several stages 
during purification using SDS-PAGE 
electrophoresis, and quantified the increased 
binding affinity. Purification of rabbit IgG 
specific antibodies by precipitation with 
caprylic acid was compared to that 1) by 
sequential precipitation with ammonium sulfate 
2) by Cygnus CHO HCP ELISA kit. In terms of 
purity of antibodies, precipitation with caprylic 
acid (99%) is more efficient than the 
ammonium sulfate method (77%). It should also 
be noted that precipitation with caprylic acid is 
associated with an increase in the affinity of 
some antibodies and is suitable to purify rabbit 
IgG. Electrophoretically separated proteins were 
transferred from a SDS-PAGE to a 
nitrocellulose membrane in the presence of 
transfer buffer. In addition, ELISA results 
confirmed that elution of IGg from the cation 
exchange matrix was also a very important step 
to optimize.  The ELISA results were also 
confirmed by immunoblot analysis of the IGg 
purification. ELISA test was performed to 




measure the rate of contamination of hepatitis B 
vaccine by Pichia pastoris proteins, using 
purified and mono-specific antibody on 23 
samples three times (table2). Also Pasteur 
Institute of Iran, Hepatitis B vaccine 
contamination rate was measured by Cygnus 
CHO HCP ELISA kit.                                                                                      
Table2: Specificity and sensitivity comparison of purified mono-specific antibody from chromatography by ELISA and 
















1 60.79 26.77 13 50.39 11.13 
2 38.09 37.17 14 75.75 54.43 
3 48.65 44.97 15 70.15 51.53 
4 174.29 151.67 16 109.09 113.27 
5 30.52 23.17 17 137.35 105.27 
6 37.52 33.97 18 43.52 41.73 
7 0.72 0.00 19 61.35 32.10 
8 47.55 8.93 20 160.75 124.30 
9 64.62 47.33 21 16.19 14.33 
10 49.25 44.67 22 71.95 15.63 
11 69.85 0.00 23 148.55 80.63 
12 65.29 28.90    
 
Sensitivity and specificity of ELISA was 
performed for both antibodies using the 
following formula 
 
The results indicate that the sensitivity and 
specificity of produced antibody is higher than 
commercial kit (table3).  
 





Contamination of intravenous solutions with 
unwanted macromolecules can cause allergy 
and numerous adverse reactions in human, so, 
quality control of these products is very 
important [1,27,28]. Identification and 
assessment of host cell protein contamination 
in hepatitis B vaccine has important role in 
quality control tests [7]. According to World 
Health Organization, contamination rate 
lt Mono-specific Ab Kit 
FP 0 0 
TP 23 23 
FN 0 2 
TN 1 1 




should not be more than 0.1 micrograms per 
dose of vaccine [9]. Confidence in the 
quantitative nature of a given HCP assay, and 
the validity of analytical measurement 
obtained by the assay, is dependent upon 
empirical demonstration of the unique 
stoichiometry of the HCP assay reagents. In 
conjunction with other analytical and 
validation methods, an HCP immunoassay 
may be thought of as a necessary quantitative 
tool for the optimization and validation of 
biopharmaceutical purification process 
efficiency and consistency, rather than as an 
end in itself. Production batches of the 
Hepatitis B vaccine should be tested by the 
National Control Laboratory (NCL) before 
being released to the market. 
In production of biological products that use in 
diagnostic kits, purification has the highest 
production cost. Now several companies 
produce several commercial kits for 
identification and assessment of host cell 
protein contamination based on ELISA and 
Western blot methods [4, 8, 10]. But high 
prices, commercial quality, difference in 
sensitivity and lack of easy access to these 
kits, sometimes create problems. Commercial 
enzyme-linked immunosorbent assay (ELISA) 
kits for the determination of contaminant have 
been used frequently as an important method 
for tests. With the constant need for validation 
procedures, an ELISA that could be employed 
to determine the recombinant hepatitis B 
vaccines was established using mono-specific 
antibodies. 
The development of hepatitis B vaccine was 
described in yeast cell origin. HBsAg was 
produced in recombinant yeast cell culture. 
Now the purified anti pichia pastoris antibody 
in several quality control measures are 
available to ensure clients are supplied with 
the highest quality of purified proteins [25].  
The results of research conducted by Mohanty 
JG, Elazhary Y suggests that IgG prepared by 
ammonium sulfate is better than that by 
caprylic acid method but the results of this 
research indicated the superiority of serum 
proteins purification by caprylic acid method 
[29]. The present investigation shows that 
producing standard mono-specific antibodies 
by laboratories of recombinant vaccine 
production centers, in addition to lack of need 
for commercial kits, can test host cell protein 
contamination of the vaccine and increases the 
quality of productions than enter marketing. It 
can be concluded that production and use of 
mono-specific antibodies for recombinant 
products quality control leads to more 
desirable and cost effective results [12, 13]. 
Since the recombinant hepatitis B vaccine is 
an important production in Pasteur Institute of 
Iran, the needful researches has been done on 
this product. It is to be mentioned that the 
achieved results could be forecasted on other 
recombinant products.  
The use of mono-specific antibody produced 
“in house” specific for HCP of the hepatitis B 
virus (HBV) vaccine can result in the 
production of a sensitive, highly specific and 
stable ELISA [4, 13, 16].       
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